Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication

Table 3 Adverse events and compliance n (%)

Adverse events	PBMT-7 (n = 478)	PBMT-14 (n = 222)	P-value
Bloating/dyspepsia	3 (0.6)	7 (3.2)
Dry mouth	4 (0.8)	0 (0.0)
Taste distortion	2 (0.4)	1 (0.5)
Epigastric discomfort	15 (3.1)	5 (2.3)
Nausea	16 (3.3)	13 (5.9)
Diarrhea	8 (1.7)	7 (3.2)
Urticaria	3 (0.6)	3 (1.4)
Headache	0 (0.0)	1 (0.5)
Chest discomfort	0 (0.0)	1 (0.5)
Total	51 (10.7)	38 (17.1)	0.487
Compliance	468 (97.9)	214 (96.4)	0.304

PBMT-7: 7-d bismuth-based quadruple therapy; PBMT-14: 14-d bismuth-based quadruple therapy.